Literature DB >> 26111068

SmartArc-based volumetric modulated arc therapy can improve the middle ear, vestibule and cochlea sparing for locoregionally advanced nasopharyngeal carcinoma: a dosimetric comparison with step-and-shoot intensity-modulated radiotherapy.

J Gao1, T-L Qian1, C-Z Tao1, Y-H Zhang1, Y Zhou1, J Yang1, J He1, R Wang1, P-J Zhou1.   

Abstract

OBJECTIVE: Radiation-induced sensorineural hearing loss is a common complication after radiotherapy in patients with nasopharyngeal carcinoma (NPC) that significantly affects their quality of life. The goal of this study was to compare SmartArc-based volumetric modulated arc therapy (VMAT-S) with step-and-shoot intensity-modulated radiation therapy (IMRT) for patients with locoregionally advanced NPC with regard to the sparing effect on middle ear, vestibule and cochlea.
METHODS: 20 patients with non-metastatic Stage III or IV NPC were selected to have planning with VMAT-S and IMRT [using Philips Pinnacle Planning System (Philips, Fitchburg, WI) for Varian accelerator] for dosimetric comparison. Mean middle ears, vestibule and cochlea doses for the two planning techniques were compared using a paired t-test. Target coverage and dose homogeneity were evaluated by calculating conformity index (CI) and homogeneity index (HI) values.
RESULTS: VMAT-S had significantly improved homogeneity and conformity compared with IMRT. Mean HI of planning target volume of gross tumour volume (PGTV) was better with VMAT-S (1.05 ± 0.02) than IMRT (1.09 ± 0.03) (p < 0.001). Mean CI of PGTV is also better with VMAT-S (0.59 ± 0.12) than IMRT (0.54 ± 0.12) (p < 0.001). Mean doses to the left cochleas were 43.8 ± 3.6 and 47.8 ± 4.0 (p < 0.001) for VMAT-S and IMRT plans, respectively. Mean doses to the right cochleas were 42.7 ± 4.7 and 47.6 ± 5.4 (p < 0.001) for VMAT-S and IMRT plans, respectively. VMAT-S also significantly reduced the mean doses to middle ears (p < 0.001 for both) and vestibule (p < 0.001 for both).
CONCLUSION: Our results indicate that VMAT-S provides better sparing of hearing apparatus in locoregionally advanced NPC. ADVANCES IN KNOWLEDGE: VMAT-S can improve the middle ear, vestibule and cochlea sparing in patients with locoregionally advanced NPC.

Entities:  

Mesh:

Year:  2015        PMID: 26111068      PMCID: PMC4743565          DOI: 10.1259/bjr.20150052

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  31 in total

1.  Impact of prolonged fraction delivery times simulating IMRT on cultured nasopharyngeal carcinoma cell killing.

Authors:  Xiao-Kang Zheng; Long-Hua Chen; Wen-Jun Wang; Feng Ye; Jia-Bing Liu; Qi-Sheng Li; Hen-Wen Sun
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-01       Impact factor: 7.038

2.  Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma.

Authors:  Jeffrey Kit Loong Tuan; Tam Cam Ha; Whee Sze Ong; Tian Rui Siow; Ivan Weng Keong Tham; Swee Peng Yap; Terence Wee Kiat Tan; Eu Tiong Chua; Kam Weng Fong; Joseph Tien Seng Wee
Journal:  Radiother Oncol       Date:  2012-01-24       Impact factor: 6.280

3.  Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.

Authors:  Wong Kein Low; Song Tar Toh; Joseph Wee; Stephanie M C Fook-Chong; De Yun Wang
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

4.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

5.  Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT.

Authors:  Eugenio Vanetti; Alessandro Clivio; Giorgia Nicolini; Antonella Fogliata; Sarbani Ghosh-Laskar; Jai Prakash Agarwal; Ritu Raj Upreti; Ashwini Budrukkar; Vedang Murthy; Deepak Dattatray Deshpande; Shyam Kishore Shrivastava; Ketayun Ardeshir Dinshaw; Luca Cozzi
Journal:  Radiother Oncol       Date:  2009-01-20       Impact factor: 6.280

6.  A study of middle ear function in the treatment of nasopharyngeal carcinoma with IMRT technique.

Authors:  Sheng Zi Wang; Ji Li; Curtis T Miyamoto; Fu Chen; Li Fen Zhou; Hai Yan Zhang; Gang Yang; Wei Fang Wang; Ming Guo; Xiao Chen Ni; Lei Wang
Journal:  Radiother Oncol       Date:  2009-10-21       Impact factor: 6.280

7.  Incidence of long-term ipsilateral and contralateral ototoxicity following radiotherapy for nasopharyngeal carcinoma.

Authors:  Hiroyuki Wakisaka; Hiroyuki Yamada; Kazumi Motoyoshi; Toru Ugumori; Hirotaka Takahashi; Masamitsu Hyodo
Journal:  Auris Nasus Larynx       Date:  2010-06-11       Impact factor: 1.863

8.  Relationship between cisplatin administration and the development of ototoxicity.

Authors:  Jeany M Rademaker-Lakhai; Mirjam Crul; Lot Zuur; Paul Baas; Jos H Beijnen; Yvonne J W Simis; Nico van Zandwijk; Jan H M Schellens
Journal:  J Clin Oncol       Date:  2006-02-20       Impact factor: 44.544

9.  Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.

Authors:  Charlotte L Zuur; Yvonne J Simis; Pauline E Lansdaal; Augustinus A Hart; Coen R Rasch; Jan H Schornagel; Wouter A Dreschler; Alfons J Balm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-06       Impact factor: 7.038

10.  Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis.

Authors:  Ladan Saleh-Ebrahimi; Felix Zwicker; Marc W Muenter; Marc Bischof; Katja Lindel; Juergen Debus; Peter E Huber; Falk Roeder
Journal:  Radiat Oncol       Date:  2013-01-24       Impact factor: 3.481

View more
  4 in total

1.  Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma.

Authors:  Enkelejda Lamaj; Erwin Vu; Janita E van Timmeren; Chiara Leonardi; Louise Marc; Izabela Pytko; Matthias Guckenberger; Panagiotis Balermpas
Journal:  Radiat Oncol       Date:  2021-04-01       Impact factor: 3.481

Review 2.  Mechanism and Protection of Radiotherapy Induced Sensorineural Hearing Loss for Head and Neck Cancer.

Authors:  Wenxia Shi; Xue Hou; Xueying Bao; Wei Hou; Xuehua Jiang; Lixin Ma; Xin Jiang; Lihua Dong
Journal:  Biomed Res Int       Date:  2021-12-21       Impact factor: 3.411

3.  Prospective matched study on comparison of volumetric-modulated arc therapy and intensity-modulated radiotherapy for nasopharyngeal carcinoma: dosimetry, delivery efficiency and outcomes.

Authors:  Bin-Bin Chen; Shao-Min Huang; Wei-Wei Xiao; Wen-Zhao Sun; Ming-Zhu Liu; Tai-Xiang Lu; Xiao-Wu Deng; Fei Han
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

4.  Dosimetric Comparisons of Volumetric Modulated Arc Therapy and Tomotherapy for Early T-Stage Nasopharyngeal Carcinoma.

Authors:  Shan Li; Qin Zhou; Liang-Fang Shen; Huan Li; Zhan-Zhan Li; Zhen Yang; Ming-Jun Lei; Xiao-Yu Yang; Zi-Jian Zhang; Yong-Mei Hu; Ze-Fu Jin; Gui Liu; Zhi-Ping Lv; Xin-Qiong Huang
Journal:  Biomed Res Int       Date:  2018-06-04       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.